Background Convalescent plasma has been widely used to treat COVID-19 and is under
investigation in numerous randomized clinical trials, but results are publicly available only …

The COVID-19 pandemic has put healthcare infrastructures and our social and economic
lives under unprecedented strain. Effective solutions are needed to end the pandemic while …

Background Early administration of convalescent plasma obtained from blood donors who
have recovered from coronavirus disease 2019 (Covid-19) may prevent disease …

The spread of SARS-CoV-2 over the entire world is more commonly known as COVID-19.
COVID-19 has impacted society in every aspect of routine life. SARS-CoV-2 infection is often …

Introduction Patients with primary or secondary immunodeficiency (PID or SID) face
increased insecurity and discomfort in the light of the COVID-19 pandemic, not knowing if …

Determining the sustainability of antibodies targeting severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) is essential for predicting immune response against the …

Convalescent plasma (CP) from patients recovered from COVID-19 is one of the most
studied anti-viral therapies against SARS-COV-2 infection. The aim of this study is to …

Background: Coronavirus continues to spread worldwide, causing various health and
economic disruptions. One of the most important approaches to controlling the spread of this …

The persistence of immunogenicity in patients with immune-mediated inflammatory diseases
(IMID) on disease-modifying antirheumatic therapy (DMARD) has been less well studied …

In some diseases, due to the restrictive availability of vaccines on the market (eg, during the
early emergence of a new disease that may cause a pandemic such as COVID-19), the use …